Search results for "phosphatidylethanolamine"

showing 10 items of 51 documents

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

Frequent Alteration of the Yin Yang 1/Raf-1 Kinase Inhibitory Protein Ratio in Hepatocellular Carcinoma

2011

The transcription factor Yin Yang 1 (YY1) can favor several aspects of tumorigenesis. In turn, Raf-1 Kinase Inhibitor Protein (RKIP) inhibits the oncogenic activities of MAPK and NF-κB pathways and promotes drug-induced apoptosis. Mutual influences between YY1 and RKIP may exist, and there are already separate evidences that relevant increases in YY1 and reductions in RKIP occur in hepatocellular carcinoma (HCC). However, the levels of the two factors have never been concomitantly examined in HCC. We evaluated by RT-PCR the mRNA levels of YY1, YY1AP, RKIP, and survivin in 35 clinical HCCs (91% HCV-related), in their adjacent cirrhotic tissues and in 6 healthy livers. Immunohistochemical ana…

AdultLiver CirrhosisMaleMAPK/ERK pathwayCarcinoma HepatocellularSettore MED/09 - Medicina InternaSurvivinCell Cycle ProteinsPhosphatidylethanolamine Binding ProteinSettore MED/08 - Anatomia PatologicaBiologymedicine.disease_causeBiochemistryInhibitor of Apoptosis ProteinsSurvivinGeneticsmedicineHumansRNA MessengerHepatocellular carcinomaYY1RKIPMolecular BiologyTranscription factorYY1 Transcription FactorAgedAged 80 and overSettore MED/12 - GastroenterologiaHepatocellular carcinoma Yin Yang 1 Raf-1 Kinase Inhibitor Protein Yin Yang 1-associated proteinKinaseYY1Liver NeoplasmsNuclear ProteinsMiddle AgedHCCSmedicine.diseaseGene Expression Regulation NeoplasticLiverHepatocellular carcinomaembryonic structuresSettore BIO/14 - FarmacologiaCancer researchMolecular MedicineFemaleSettore SECS-S/01 - StatisticaCarcinogenesisTranscription FactorsBiotechnologyOMICS: A Journal of Integrative Biology
researchProduct

Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I

1998

Plasmas of patients with Tangier disease (TD) lack lipid-rich α-HDL which, in normal plasma, constitutes the majority of high density lipoprotein (HDL). Residual amounts of apolipoprotein (apo)A-I in TD plasma occur as lipid-poor or even lipid-free preβ-HDL. By contrast to normal plasma, TD plasma does not convert preβ-HDL into α-HDL. Moreover, fibroblasts of TD patients were found to be defective in secreting cholesterol or phospholipids in the presence of lipid-free apoA-I. We have therefore hypothesized that both defective conversion of preβ-HDL into α-HDL and defective lipid efflux from TD cells onto lipid-free apoA-I result from a disturbance in phospholipid transfer occurring in both …

AdultMaletransferring phospholipidsPhospholipidTangier diseasePhosphatidic AcidsQD415-436PhosphatidylinositolsBiochemistrychemistry.chemical_compoundEndocrinologyTangier diseasePhosphatidylcholinePhospholipid transfer proteinExtracellularmedicineHumansCells CulturedPhosphatidylethanolamineApolipoprotein A-ICholesterolPhosphatidylethanolaminesReverse cholesterol transportnutritional and metabolic diseasesBiological TransportCell BiologyFibroblastsmedicine.diseaseMolecular biologyfamilial HDL deficiencyreverse cholesterol transportLipoproteins LDLphospholipid transfer proteinsprebeta-HDLTangier disease; transferring phospholipidschemistryPhosphatidylcholinesFemalelipids (amino acids peptides and proteins)cholesterol efflux
researchProduct

Patterns of Innate or Acquired Resistance to Anticancer Drugs: Our Experience to Overcome It

2021

Drug resistance, which is often of a multiple type, can be defined as the ability of cancer cells to obtain resistance to both conventional and novel chemotherapy agents. It remains a major problem to solve in cancer therapy. The mechanisms of resistance are multifactorial, and in our cellular models of acute myeloid leukemia, hepatocellular carcinoma, and triple-negative breast cancer, it involves the NF-κB pathway. In our opinion, multitarget molecules can be considered as privileged compounds capable of attacking and reversing the resistant phenotype. In the phenomena of both innate and acquired drug resistance that we have been studying since 1998 to today and up to 2016 under the guida…

Cancer ResearchAntineoplastic AgentsApoptosisPhosphatidylethanolamine Binding ProteinDrug resistanceMetastasisBreast cancerdrug resistance P-glycoprotein IAP NF-κBNeoplasmsHumansMedicineATP Binding Cassette Transporter Subfamily B Member 1Transcription factorYY1 Transcription FactorP-glycoproteinbiologybusiness.industryKinaseNF-kappa BMyeloid leukemiamedicine.diseaseDrug Resistance NeoplasmCancer cellSettore BIO/14 - Farmacologiabiology.proteinCancer researchbusinessCritical Reviews™ in Oncogenesis
researchProduct

Analysis of Possible Mechanisms Accounting for Raf-1 Kinase Inhibitor Protein Downregulation in Hepatocellular Carcinoma

2012

Abstract Raf-1 kinase inhibitor protein (RKIP) is a tumor and metastasis suppressor that promotes drug-induced apoptosis in cancer cells. It is frequently downregulated, both at the mRNA and protein level, in hepatocellular carcinoma (HCC), but the mechanisms leading to this reduction are obscure. We sequenced the whole RKIP gene in three human HCC cell lines (HA22T/VGH, HepG2, and Hep3B), and in five clinical HCC samples, but could not find any gene variant that might account for their low RKIP levels. We also examined whether gene methylation may be responsible for the altered RKIP expression. No methylation of the RKIP gene was found in the tumor samples, while among the cell lines only …

Carcinoma HepatocellularLeupeptinsAntineoplastic AgentsPhosphatidylethanolamine Binding ProteinRKIP (Raf-1 kinase inhibitor protein) hepatocellular carcinomaBiologyBiochemistryDownregulation and upregulationRNA interferenceCell Line TumorGeneticsHumansMetastasis suppressorPromoter Regions GeneticMolecular BiologyRegulation of gene expressionKinaseLiver NeoplasmsHep G2 CellsMethylationDNA Methylationdigestive system diseasesGene Expression Regulation NeoplasticMicroRNAsMutationCancer cellDNA methylationAzacitidineSettore BIO/14 - FarmacologiaCancer researchMolecular MedicineRNA InterferenceBiotechnologyOMICS: A Journal of Integrative Biology
researchProduct

Sphingomyelin inhibition of Ciona intestinalis (Tunicata) cytotoxic hemocytes assayed against sheep erythrocytes

1995

Hemocytes from the ascidian, Ciona intestinalis, are capable of lysing erythrocytes in vitro following cell membrane contact. With the aim of examining the mechanism of cytotoxicity, we performed inhibition experiments with lipid components of erythrocyte membranes. Cholesterol is not an inhibitor, whereas, among the phospholipids tested, (sphingomyelin, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine) sphingomyelin inhibits the hemolytic activity of hemocytes. However, thin layer chromatography showed that sphingomyelinase activity was not contained in the chloroform-methanol extracts from hemocyte debris. The inhibition capacity of the components ceramide and phosphorylc…

Cell ExtractsHemocytesCiona intestinaliCytotoxicityHemocyteTunicate;Cell membraneHemolysin Proteinschemistry.chemical_compoundSphingomyelin inhibition;InvertebratePhospholipidsCiona intestinalis;biologyInvertebrate;PhosphatidylserineCiona intestinalisSphingomyelinsCytotoxicity;Sheep erythrocytesCholesterolSphingomyelin Phosphodiesterasemedicine.anatomical_structureBiochemistrylipids (amino acids peptides and proteins)SphingomyelinHemolysis inhibitionSphingomyelin inhibitionCeramideHemolysis inhibition;ImmunologyTunicateHemolysisMembrane LipidsPhosphatidylcholinemedicineAnimalsCiona intestinalisPhosphatidylethanolamineSheepPhosphorylcholineCell MembraneOsmolar ConcentrationCytotoxicity Tests Immunologicbiology.organism_classificationCulture MediaHemocytes;chemistryChromatography Thin LayerDevelopmental Biology
researchProduct

Inhalable Formulation Based on Lipid–Polymer Hybrid Nanoparticles for the Macrophage Targeted Delivery of Roflumilast

2022

Here, novel lipid-polymer hybrid nanoparticles (LPHNPs), targeted to lung macrophages, were realized as potential carriers for Roflumilast administration in the management of chronic obstructive pulmonary disease (COPD). To achieve this, Roflumilast-loaded fluorescent polymeric nanoparticles, based on a polyaspartamide-polycaprolactone graft copolymer, and lipid vesicles, made from 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-distearoyl-sn-glycero-phosphoethanolamine-N-(polyethylene glycol)-mannose, were properly combined using a two-step method, successfully obtaining Roflumilast-loaded hybrid fluorescent nanoparticles (Man-LPHFNPs@Roflumilast). These exhibit colloidal size and a ne…

CyclopropanesPolymers and PlasticsPolymersMacrophagesPhosphatidylethanolaminesAminopyridinesBioengineeringPolyethylene GlycolsBiomaterialsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBenzamidesMaterials ChemistryHumansNanoparticlesParticle SizeMannoseBiomacromolecules
researchProduct

Euzebyella saccharophila gen. nov., sp. nov., a marine bacterium of the family Flavobacteriaceae.

2010

Strain 7SM30T , an aerobic marine, Gram-negative, heterotrophic and yellow- to orange-pigmented bacterium isolated from seawater from Castellón, Spain, was characterized using a polyphasic approach. Analysis of the 16S rRNA gene sequence showed that the isolate represented a novel lineage within the family Flavobacteriaceae. The most closely related genera were Pseudozobellia, Zobellia and Kriegella. Cells of strain 7SM30T were non-motile rods that required sea salts for growth, used a wide variety of carbohydrates as sole carbon and energy sources and, unlike species of the genera Pseudozobellia and Zobellia, did not possess flexirubin-type pigment or hydrolyse agar. Strain 7SM30T containe…

DNA BacterialSequence analysisMolecular Sequence DataEMENDED DESCRIPTIONMicrobiologyMicrobiologyPhylogeneticsRNA Ribosomal 16SSeawaterEcology Evolution Behavior and SystematicsPhylogenyBase CompositionbiologyPigmentationPhosphatidylethanolaminesTAXAFatty AcidsVitamin K 2General MedicineSequence Analysis DNARibosomal RNAbiology.organism_classification16S ribosomal RNAFlavobacteriaceaeBacterial Typing TechniquesType speciesSpainEnergy sourceFlavobacteriaceaeBacteriaInternational journal of systematic and evolutionary microbiology
researchProduct

Phospholipid-polyaspartamide micelles for pulmonary delivery of corticosteroids

2011

A novel drug delivery system for beclomethasone dipropionate (BDP) has been constructed through self-assembly of a pegylated phospholipid-polyaminoacid conjugate. This copolymer was obtained by chemical reaction of α,β-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA) with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)2000] (DSPE-PEG(2000)-NH(2)). Benefiting from the amphiphilic structure with the hydrophilic shell based on both PHEA and PEG and many hydrophobic stearoyl tails, PHEA-PEG(2000)-DSPE copolymer was able to self assemble into micelles in aqueous media above a concentration of 1.23 × 10(-7)M, determined by fluorescence studies. During the self-assembling …

ErythrocytesBiocompatibilityCell SurvivalDrug CompoundingDrug StorageALPHABETA-Poly(N-2-hydroxyethyl)-dl- aspartamide (PHEA) 12-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)2000](DSPE-PEG2000-NH2) Polymeric micelles Drug delivery Beclomethasone dipropionate (BDP) Pulmonary diseasesPhospholipidPharmaceutical Science[object Object]HemolysisMicelleCell LinePolyethylene Glycolschemistry.chemical_compoundDrug StabilityAmphiphilePEG ratioPulmonary diseasesHumans?Beclomethasone dipropionate (BDP)Particle SizeLungMicellesDrug CarriersChromatographyAqueous solutionMolecular StructureChemistryPhosphatidylethanolaminesBeclomethasonetechnology industry and agriculture?-Poly(N-2-hydroxyethyl)-dl-aspartamide (PHEA)Spectrometry FluorescenceSolubilitySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryDrug deliveryPolymeric micellesNanocarriersPeptidesHydrophobic and Hydrophilic InteractionsNuclear chemistry
researchProduct

Liver fatty acid composition in the spontaneously diabetic BB rat.

1991

The purpose of the present experiment was to investigate if the modulation by insulin of liver microsomal desaturase activities in the spontaneously diabetic adult male Bio-Breeding (BB) rat, with destructive insulitis resembling the lesions described in the human Type I (insulin-dependent) diabetes, corresponds to modifications in fatty acid composition, reflect of changes in fatty acid desaturation. We observed no significant differences between BB rats, during the hyper-(48 h), the normo-(17 h) and the hypo-glycemic (3 h) periods which followed the insulin injection, and control rats for the fatty acid composition of liver total lipids, phosphatidylethanolamines, phosphatidylcholines, tr…

Fatty Acid DesaturasesMalemedicine.medical_specialtymedicine.medical_treatmentLinoleic acidArachidonic AcidsBiologyDiabetes Mellitus ExperimentalLinoleic Acidchemistry.chemical_compoundDiabetes mellitusInternal medicinemedicineAnimalsInsulinRats Inbred BBTriglycerideschemistry.chemical_classificationArachidonic AcidCholesterolInsulinPhosphatidylethanolaminesFatty AcidsFatty acidGeneral Medicinemedicine.diseaseLipid MetabolismRatsEndocrinologychemistryLinoleic AcidsLiverMicrosomeMicrosomes LiverPhosphatidylcholinesArachidonic acidCholesterol EstersInsulitisArchives internationales de physiologie, de biochimie et de biophysique
researchProduct